Search clinical trials for: Azilsartan Trimethylethanolamine

Total 79 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

Health

China
Lee's Pharmaceutical Limited
Zhaoke (Guangzhou) Pharmaceutical Limited

Completed

Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

Bioequivalence of Two Azilsartan Formulations

Hong Kong
Lee's Pharmaceutical Limited

Completed

Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers

Hypertension
Hospital General de México Dr. Eduardo Liceaga

Unknown

Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients

Hypertension | Obesity | Type 2 Diabetes Mellitus

Mexico
Takeda

Completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Hypertension

Japan
Arbor Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Hypertension

United States, Brazil, Turkey, Poland, Mexico, Colombia, Italy, Argentina, Bulgaria, Hungary, South Africa, Ukraine
University of Chicago
Takeda

Completed

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Hypertension

United States
Nara Medical University

Completed

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering (NARA)

Hypertension

Japan
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Takeda

Completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Hypertension

Japan
Takeda

Withdrawn

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE)

Essential Hypertension With Stable Angina and Dyslipidemia

Japan
Takeda

Completed

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Pediatric Hypertension

Japan
Takeda

Completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Hypertension

Russian Federation, Kazakhstan
Takeda

Completed

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Type 2 Diabetes Mellitus | Essential Hypertension

Taiwan, Thailand, China
Takeda

Terminated

Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Research Institute for Complex Problems of Cardiovascular...

Completed

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)

Diabetes Mellitus | Arterial Hypertension | Stable Chronic Angina

Russian Federation
Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

Diabetic Kidney Disease | Proteinuria | Blood Pressure | Kidney Dysfunction

China
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

Hypertension

Korea, Republic of
Takeda

Completed

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Pediatric Hypertension

Japan
Takeda

Terminated

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

Hypertension

United States, United Kingdom
Takeda

Recruiting

A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure

Hypertension

Japan
Takeda

Completed

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Essential Hypertension Complicated by Type 2 Diabetes Mellitus

Japan
Chelsea Therapeutics
Chiltern International Inc.

Completed

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa (NOH301)

Primary Autonomic Failure | Dopamine Beta Hydroxylase Deficiency | Symptomatic Neurogenic Orthostatic Hypotension (NOH) | Non-diabetic Neuropathy

United States, Canada
Celltrion

Completed

A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers

Health, Subjective

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Bronx VA Medical Center
Chelsea Therapeutics

Completed

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Hypotension | Spinal Cord Injury

United States
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Russian Federation
New York Medical College
Lundbeck LLC

Active, not recruiting

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

Postural Tachycardia Syndrome (POTS) | Fainting | Vasovagal Syncope (VVS)

United States
China Medical University Hospital

Unknown

Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue

Stroke | Fatigue

Taiwan
Takeda

Completed

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Hypertension

United States, Argentina, Peru, Mexico
Takeda

Completed

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Essential Hypertension

Italy, Poland, Spain, Bulgaria, Serbia, Netherlands, Estonia, Hungary, Germany, Sweden, Lithuania, Slovakia, United Kingdom, France
Takeda

Completed

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Essential Hypertension
Takeda

Completed

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Hypertension
Beijing Tsinghua Chang Gung Hospital

Not yet recruiting

Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension (AZAF)

Hypertension | Atrial Fibrillation

China
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Essential Hypertension

China
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Takeda

Terminated

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Argentina, Mexico, Chile, Peru
Takeda

Completed

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Argentina, Mexico, Peru, Chile
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Takeda

Completed

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Chile, Mexico
Takeda

Completed

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Grade I or II Essential Hypertension

Japan
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Hypertension

United States
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

Hypertension

United States, Chile, Russian Federation, Mexico, Peru
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Yan Li

Active, not recruiting

Antihypertensive Treatment in Masked Hypertension for Target Organ Protection (ANTI-MASK)

Masked Hypertension

China
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Terminated

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (ARBs CORONA II)

Covid19 | SARS-CoV Infection

Canada, France
Takeda

Completed

Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"

Hypertension

Japan

3

Subscribe